Last updated: 28 March 2018 at 8:25am EST

David Mnea Partners 14, L.P... Net Worth




The estimated Net Worth of David Mnea Partners 14, L.P... is at least 239 千$ dollars as of 27 March 2018. David P owns over 707,964 units of TRACON Pharmaceuticals Inc stock worth over 239,154$ and over the last 7 years David sold TCON stock worth over 0$.

David P TCON stock SEC Form 4 insiders trading

David has made over 1 trades of the TRACON Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently David bought 707,964 units of TCON stock worth 1,911,503$ on 27 March 2018.

The largest trade David's ever made was buying 707,964 units of TRACON Pharmaceuticals Inc stock on 27 March 2018 worth over 1,911,503$. On average, David trades about 707,964 units every 0 days since 2018. As of 27 March 2018 David still owns at least 3,466,003 units of TRACON Pharmaceuticals Inc stock.

You can see the complete history of David P stock trades at the bottom of the page.



Insiders trading at TRACON Pharmaceuticals Inc

Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over 6,301,907$ worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth 151,387,355$ . The most active insiders traders include Forest BaskettScott D SandellAnthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of 15,278$. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth 1,381,562$.



What does TRACON Pharmaceuticals Inc do?

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w



What does TRACON Pharmaceuticals Inc's logo look like?

TRACON Pharmaceuticals Inc logo

Complete history of David P stock trades at TRACON Pharmaceuticals Inc

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
27 Mar 2018 David Mnea Partners 14, L.P...
購入する 707,964 2.70$ 1,911,503$
27 Mar 2018
3,466,003


TRACON Pharmaceuticals Inc executives and stock owners

TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include: